Ontology highlight
ABSTRACT:
SUBMITTER: Lukashchuk V
PROVIDER: S-EPMC4756767 | biostudies-literature | 2016
REPOSITORIES: biostudies-literature
Lukashchuk Vera V Lewis Katherine E KE Coldicott Ian I Grierson Andrew J AJ Azzouz Mimoun M
Molecular therapy. Methods & clinical development 20160217
Current barriers to the use of adeno-associated virus serotype 9 (AAV9) in clinical trials for treating neurological disorders are its high expression in many off-target tissues such as liver and heart, and lack of cell specificity within the central nervous system (CNS) when using ubiquitous promoters such as human cytomegalovirus (CMV) or chicken-β-actin hybrid (CAG). To enhance targeting the transgene expression in CNS cells, self-complementary (sc) AAV9 vectors, scAAV9-GFP vectors carrying n ...[more]